AIN457 (secukinumab)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

AsthmaPsoriatic Arthritis

Phase 2

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

TerminatedNCT01478360

Novartis PharmaceuticalsAsthma

Start: 2012-03-31End: 2014-11-30Updated: 2015-11-20

Phase 3

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

CompletedNCT02662985

Novartis PharmaceuticalsPsoriatic Arthritis

Start: 2016-08-22End: 2020-11-10Updated: 2021-12-07

Related Papers

POS0225 HOW WELL DOES ULTRASOUND-ASSESSED SYNOVITIS IN REDUCED JOINT SETS PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DMARDS? - EXPLORATORY RESULTS FROM A PHASE 3B STUDY

2023-05-30

E087 Reduced joint synovitis assessment versus the global EULAR OMERACT synovitis score (GLOESS) to predict the response to secukinumab in patients with active psoriatic arthritis and inadequate response to conventional disease-modifying anti-rheumatic drugs: exploratory results from the ULTIMATE trial

Lara D. Veeken2023-04-011 citations

P253 Ultrasound demonstrates continued improvement in psoriatic arthritis synovitis and enthesitis with secukinumab: 52-week results from a Phase 3 study

Lara D. Veeken2022-04-231 citations

Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE

Lara D. Veeken2021-09-1336 citations

P187 Secukinumab significantly decreased joint synovitis measured by Power Doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12week) results from a randomised, placebo-controlled Phase 3 study

Lara D. Veeken2021-04-014 citations

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.

2019-12-0416 citations